BACKGROUND: Worldwide, diabetes has become the most common cause of end-stage renal disease (ESRD), yet Swiss data are largely lacking.
Introduction
Diabetes, one of the major noncommunicable diseases in global health, has become the most common cause of endstage renal disease (ESRD) in most countries. The total cost of renal replacement therapy (RRT) to the global health insurance system has increased owing to the aging population and high prevalence of type 2 diabetes. The number of patients with ESRD receiving RRT is projected to reach 2.2 million by the year 2030 [1] [2] [3] . Overall incidence rates of ESRD, which rose for decades, began to stabilise or even fall after 2006 in several European countries (Austria, Spain, Denmark, Sweden, Norway, Finland) [4] , although they continued to increase in the USA [5] , the UK [6] , Taiwan [7] and Japan [8] . Trends in ESRD with diabetes (ESRD-DM) incidence also differed according to geography [9] . The incidence of ESRD-DM has increased in the UK over the past 10 years [6] , as well as in France [10] , while it stabilised at the end of the 2000s in the USA and has decreased since 2006 in the USA, Denmark [11] , Australia and New Zealand [12] . An understanding of these basic differences in the epidemiology of diabetic nephropathy is of great importance to the development and implementation of prevention and management strategies. Several prospective and observational studies, including those from the Dialysis Outcomes and Practice Patterns Study (DOPPS), the United States Renal Data System (USRDS) and the European Renal Association -European Dialysis and Transplantation Association (ERA-EDTA) Registry have offered insights into the characteristics and prognosis of patients with ESRD, including ESRD-DM patients. Since Switzerland is not represented in these databases, local epidemiological data are largely lacking. In order to evaluate the prevalence of ESRD-DM and its possible progression over time, we carried out a multicentre study in the Canton of Vaud of Switzerland with a referral population of around 750 000 inhabitants. The primary goal of this study was to assess the prevalence and compare the characteristics of diabetic subjects on renal replacement therapy (RRT) on 31 December 2009 with those on RRT on 31 December 2014. The secondary goals were to examine the 5-year mortality rate of diabetic subjects on RRT on 31 December 2009 and to examine the total number of new cases of diabetic patients on RRT during the 5-year period.
Methods
In collaboration with the dialysis facilities of the Canton of Vaud, all files of patients with the diagnosis of diabetes and on RRT for more than 3 months on 31 December 2009 and on 31 December 2014 were carefully examined onsite. We collected the sociodemographic, clinical, laboratory and healthcare characteristics of patients actively on RRT on 31 December 2009 and 2014 and their 5-y survival rate. The body mass index (BMI) calculation was based on the dry weights listed at the end of 2009 and 2014. Laboratory values were considered valid for listing if obtained within 3 months prior to data collection. Systolic and diastolic blood pressure values before dialysis were averaged from three listed blood pressure measurements from the three last consecutive dialysis sessions of the year. The same was done for systolic and diastolic blood pressure values measured at the end of dialysis. The diagnostic criteria for diabetes were consistent with the American Diabetes Association (ADA) 2008 clinical practice guideline [13] . The diagnosis of macrovascular complications, coronary artery disease, peripheral artery disease, stroke and other complications were based on the listing of diagnoses in the patient file. 
Results
On 31 The estimated 5-year mortality rate was 61.7%, based on the outcomes of 98 diabetic patients listed by the end of Haemoglobin (g/l) 117.9 10.9 112.3 11.6 p<0.001 CAD = coronary artery disease; DBP = diastolic blood pressure; HbA1c = glycated haemoglobin; HR = heart rate; PAD = peripheral artery disease; SBP = systolic blood pressure 
Discussion
According to data from the International Diabetes Federation [14] , the prevalence of diabetes in adults aged between 20 and 79 years was 7.7% in 2015, with a total estimated number of 480 700 adults with diabetes in Switzerland. Diabetes has already become the most prevalent noncommunicable disease in developed countries, and its epidemic increase has also reached developing countries. Data from USRDS has demonstrated that the number of incident ES-RD cases with diabetes as the primary cause has been rising rapidly since 1980 [4] . Data from Switzerland are lacking. The Swiss Society of Nephrology has only recently (in 2013) created the Swiss Renal Registry and Quality Assessment Program (SRRQAP) in order to collect information in the dialysis population. Other epidemiological RRT studies in Switzerland have demonstrated that quality of care influences survival [15] , that survival rates compared favourably with those in other countries and did not differ in diabetic patients [16] , and finally that there was an overall increase in the elderly dialysis population with time [17] . In a prior study reported by Golshayan et al. [18] , the prevalence of diabetes among ESRD patients was 23% in 1999 in Canton Vaud, with a total of 43 diabetic patients on RRT. Our study is the first to focus specifically on the clinical characteristics of patients with diabetes on RRT and to describe the epidemiological changes over 5 years of ES-RD-DM patients in Canton Vaud, Switzerland. In our study, the prevalence of ESRD-DM was 38% in 2009, and increased to 47% in 2014. The increase between 1999 (23%) and 2009 (38%) could be due to aging of the population (62.1±11.2 years in 1999 vs 69.5±10.5 years in 2009). However, the mean age did not differ between 2009 and 2014, suggesting that other contributors are involved, such as the increasing prevalence of type 2 diabetes and a growing population (1.6% annual increase). Of interest, at the end of 2015, the SRRQAP register included 4215 dialysed patients. The median age of the dialysis population was 70.2 years and 33.7% had diabetes as a comorbidity, among whom 19.7% had diabetes as the primary cause of ESRD. We could not find an explanation for the difference in prevalence of diabetes in ESRD patients according to the SRRQAP registry and in our study. On the other hand, the increased prevalence of ESRD-DM and the characteristics of these patients in our study were consistent with other studies in Europe [6, 10] . From these results, we extrapolate around 400 incidental cases of ESRD-DM patients per year starting RRT in Switzerland, corresponding to 49.4 per million population which is slightly higher than the average of 32 p.m.p in most European countries [19] . Several important points were observed in our study. Firstly, there was no use of peritoneal dialysis in the treatment of ESRD-DM in 2009. The choice of dialysis modality is based on financial, cultural and socioeconomic factors, as well as experience with peritoneal dialysis and availability of haemodialysis [20] . However, after a recent Swiss national effort to promote home dialysis and to reduce the costs of RRT, more diabetic patients used peritoneal dialysis, as observed in our study, in 2014. Secondly, patients with diabetes in 2014 had more macrovascular complications than those dialysed in 2009, a difference that was mainly dictated by the increase in peripheral arterial disease. As the amputation rate had not increased, we believe that this observation was due to the increased awareness and care of the diabetic foot implemented in the Canton de Vaud in recent years, with a programme supported by the cantonal authority (Programme Cantonal Diabète). In addition, there may be a reporting bias resulting from an increase in disease listing by hospitalists under economic pressure after diagnosis-related groups (DRGs) were introduced into the payment system for inpatient care in 2012, with the intention to improve cost efficiency [21] . Thirdly, haemoglobin level decreased significantly during the study period from 117.9 g/l to 112.3 g/l, although it remained at the target level recommended by the guidelines [15] . Collectively, TREAT [22] , CREATE [23] , CHOIR [24] studies have shown that higher haemoglobin targets are associated with an increased risk of stroke and thromboembolic events in patients with chronic renal disease.
Another meta-analysis has demonstrated increased mortality associated with higher haemoglobin targets [25] . Therefore, international guidelines recommend haemoglobin levels of between 100 and 110 g/l [26] , which probably explains the decrease in haemoglobin levels observed in this study.
Fourthly, there was a decreased use of calcium-containing phosphate binders. Of note, calcium administration significantly increases calcium balance [27, 28] , which could aggravate vascular calcification and lead to increased cardiovascular mortality.
The 5-year survival rate for patients on RRT in 2009 was around 40%. Similar numbers for diabetic and nondiabetic patients have already been reported by Breidhardt et al. in a Swiss cohort study of haemodialysis patients [16] . Interestingly, in contrast to their cohort, in our study BMI was significantly higher in survivors, which is in accordance with the well-described reverse paradox in dialysis patients [29] . It also suggests that body protein-energy wasting in diabetic patients with RRT may be specifically linked to a worse outcome, as found in patients presenting with "burnt out diabetes" [30] . The finding that survival was associated with dialysis duration is possibly explained by selection bias due to the cross-sectional design of the study: patients were in general included not at the initiation of haemodialysis, but years later. It is well known that mortality rates are high the first year after dialysis initiation; these patients were underrepresented in this study [31] . Of all the 274 ESRD-DM patients treated during the 5 years, only 8.4% received a kidney transplant, which is low and underscores the need for improving access to kidney transplantation in diabetic patients.
The main limitation of the study is the retrospective analysis of patients with diabetes starting RRT but not listed in 2009 and 2014. We believe that some patients may have been missed, although the error is presumably weak. The diagnosis of diabetes may have been missed in patients presenting with burnt out diabetes and no longer on antidiabetic medication. Accurate prevalence of diabetic retinopathy is lacking in our study owing to incomplete reporting of ophthalmological examinations. Reported comorbidities were based only on the listing of diagnosis, which may have been incomplete. In conclusion, epidemiological changes in diabetes mellitus, especially type 2 diabetes, over the past 20 years have greatly influenced the epidemiology of diabetes-related kidney diseases. The marked increase in the prevalence of ESRD-DM in the Canton of Vaud, may represent a socioeconomic pressure on Swiss public health provisions.
